fluvoxamine

A third drug, fluvoxamine, also showed no benefit.

Neither ivermectin nor fluvoxamine reduced the risk of long COVID.

More than 1,100 study participants, all of whom were overweight or had obesity, were randomly assigned to one of six groups that received various combinations of metformin, the antiparasitic drug ivermectin, the antidepressant drug fluvoxamine or a placebo.

In this very well-designed New England Journal of Medicine study, researchers randomized covid patients to receive three experimental treatments: metformin, ivermectin and fluvoxamine.

The researchers recruit anyone 30 years old or older — including vaccinated individuals — to study whether existing drugs, such as fluvoxamine, now used to treat depression, can help people to get through COVID-19.